Roy Buchanan
Stock Analyst at JMP Securities
(5.00)
# 15
Out of 5,124 analysts
71
Total ratings
55.07%
Success rate
109.69%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Market Outperform | $153 → $173 | $221.03 | -21.73% | 8 | Oct 3, 2025 | |
| ASMB Assembly Biosciences | Initiates: Market Outperform | $38 | $33.75 | +12.61% | 1 | Sep 24, 2025 | |
| DVAX Dynavax Technologies | Reiterates: Market Outperform | $32 | $15.38 | +108.06% | 8 | Aug 22, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $14.41 | +73.49% | 15 | Aug 12, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $4.35 | +221.84% | 2 | Jun 17, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $10 | $4.67 | +114.13% | 9 | May 28, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.11 | +80.18% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.69 | +965.09% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $65.75 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $3.71 | +7.82% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $23 → $14 | $4.27 | +227.87% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $33 | $133.77 | -75.33% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $4.77 | +4.82% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $839.99 | -46.67% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $12.16 | +31.58% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.02 | - | 2 | Feb 16, 2023 |
Cidara Therapeutics
Oct 3, 2025
Maintains: Market Outperform
Price Target: $153 → $173
Current: $221.03
Upside: -21.73%
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $33.75
Upside: +12.61%
Dynavax Technologies
Aug 22, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $15.38
Upside: +108.06%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $14.41
Upside: +73.49%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $4.35
Upside: +221.84%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $4.67
Upside: +114.13%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.11
Upside: +80.18%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.69
Upside: +965.09%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $65.75
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $3.71
Upside: +7.82%
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $4.27
Upside: +227.87%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $133.77
Upside: -75.33%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.77
Upside: +4.82%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $839.99
Upside: -46.67%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $12.16
Upside: +31.58%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.02
Upside: -